[Study of the effects of isaxonine on retrograde axon degeneration induced by vincristine in man (author's transl)].
Fifteen patients with Hodgkin's disease were examined before and after each administration of vincristine sulfate (2 intravenous injections of 1.4 mg/m2 of body surface, during the first week of each month for 3 months). Moreover, each patient received daily, according to a double blind protocol, either 4 capsules of 375 mg of isaxonine, either 4 capsules filled with lactose used as placebo. At the end of treatment, analysis revealed that 8 subjects were given isaxonine and 7 the placebo. Motor, sensory and reflex conduction velocities, amplitudes of potentials evoked by stimulating motor, cutaneous sensory, or primary afferent fibres, were determined in each electrophysiological examination session. The data and pecularly those obtained from reflex studies, show a significant lesser degree of distal axonal degeneration, in patients receiving a placebo. These results support evidence for a protective effect of the drug against vincristine induced peripheral nerve lesions.
D004311:Double-Blind Method; D004341:Drug Evaluation; D004576:Electromyography; D006181:H-Reflex / Q000187:drug effects; D006801:Humans; D009132:Muscles / Q000187:drug effects; D009410:Nerve Degeneration / Q000187:drug effects*; D009431:Neural Conduction / Q000187:drug effects; D011115:Polyneuropathies / Q000139:chemically induced / Q000517:prevention & control*; D011743:Pyrimidines / Q000627:therapeutic use*; D014750:Vincristine / Q000009:adverse effects / Q000037:antagonists & inhibitors*
D011743:Pyrimidines; D014750:Vincristine; C020375:isaxonine
Etude des effets de l'isaxonine sur les lésions de dégénérescence axonale rétrograde induites chez l'homme par la vincristine.